Company Overview

Zivo Bioscience, Inc. is a biotechnology company focused on the development of novel biologic and immune‑modulating therapeutics derived from proprietary algal technology. The company operates primarily in the biotechnology and life sciences industries, with research emphasis on immunology, infectious disease, and inflammatory conditions. Its core business model centers on discovering, developing, and commercializing therapeutic candidates that leverage naturally derived compounds with potential broad immune‑supporting applications.

The company’s primary value driver is its proprietary platform based on algal biomass–derived bioactive compounds, which are designed to modulate immune responses rather than target single disease pathways. Zivo Bioscience traces its origins to earlier algal research initiatives and has evolved into a public biotechnology company through corporate restructuring and strategic refocusing on human and animal health applications. Its strategy emphasizes preclinical and early‑stage clinical development, with a long‑term objective of partnering or licensing successful candidates to larger pharmaceutical or animal health companies.

Business Operations

Zivo Bioscience operates as a single reporting segment focused on biologic drug discovery and development, with revenue generation currently limited and primarily associated with research collaborations, grants, or pilot programs. The company’s operations are concentrated on research and development, including preclinical testing, formulation work, and early regulatory planning. As of the most recent public disclosures, Zivo does not report material commercial product sales and remains dependent on external funding to support operations.

The company controls proprietary algal cultivation, processing, and extraction technologies, which form the foundation of its therapeutic pipeline. Zivo Bioscience has pursued collaborations with academic institutions and third‑party research organizations to advance its programs, while maintaining internal oversight of intellectual property and development strategy. Data inconclusive based on available public sources regarding any material revenue‑generating subsidiaries or long‑term joint ventures.

Strategic Position & Investments

Zivo Bioscience’s strategic direction is centered on advancing its immune‑modulating candidates through preclinical validation and into early clinical or veterinary applications. Growth initiatives focus on expanding the therapeutic scope of its algal‑derived compounds, particularly in areas where immune balance plays a critical role, such as inflammatory diseases and infectious conditions. The company emphasizes capital efficiency and staged development to manage risk typical of early‑stage biotechnology firms.

The company has disclosed investments primarily in internal research programs rather than large‑scale acquisitions. Its portfolio consists of internally developed intellectual property rather than a diversified set of acquired assets. Emerging areas of interest include the potential use of its technology in animal health and agricultural bioscience, though the commercial scale and timing of these initiatives remain uncertain based on publicly available information.

Geographic Footprint

Zivo Bioscience is headquartered in the United States, with principal operations historically based in the Midwestern United States. Its research and administrative activities are primarily domestic, with no indication of large‑scale manufacturing or commercial operations outside the U.S. as of the latest filings.

International exposure is limited and largely indirect, occurring through potential research collaborations, future licensing opportunities, or global applicability of its intellectual property. Data inconclusive based on available public sources regarding any permanent international offices or subsidiaries.

Leadership & Governance

Zivo Bioscience is led by an executive team with experience in biotechnology development, corporate governance, and life sciences research. Leadership emphasizes disciplined capital management, scientific validation, and strategic partnering as core elements of the company’s operating philosophy. The board and management team guide strategy with a focus on advancing the pipeline while maintaining compliance with public company reporting standards.

Key executives include:

• John Payne – Chief Executive Officer
• David J. Stitt – Chief Financial Officer
• Kevin L. Redding – Chief Operating Officer
• Dr. Richard A. Waldron – Chief Scientific Officer

The leadership team’s strategic vision centers on translating early‑stage scientific assets into clinically and commercially viable therapies through partnerships and incremental development milestones.